Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic society of Australia and New Zealand and lung foundation australia position statements summary

Helen E. Jo, Jyotika D. Prasad, Lauren K. Troy, Annabelle Mahar, Jane Bleasel, Samantha J. Ellis, Daniel C. Chambers, Anne E. Holland, Fiona R. Lake, Gregory Keir, Nicole S. Goh, Margaret Wilsher, Sally de Boer, Yuben Moodley, Christopher Grainge, Helen M. Whitford, Sally A. Chapman, Paul N. Reynolds, David Beatson, Leonie J. Jones & 4 others Peter Hopkins, Heather M. Allan, Ian Glaspole, Tamera J. Corte

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with debilitating symptoms of dyspnoea and cough, resulting in respiratory failure, impaired quality of life and ultimately death. Diagnosing IPF can be challenging, as it often shares many features with other interstitial lung diseases. In this article, we summarise recent joint position statements on the diagnosis and management of IPF from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia, specifically tailored for physicians across Australia and New Zealand. Main suggestions: • A comprehensive multidisciplinary team meeting is suggested to establish a prompt and precise IPF diagnosis. • Antifibrotic therapies should be considered to slow disease progression. However, enthusiasm should be tempered by the lack of evidence in many IPF subgroups, particularly the broader disease severity spectrum. • Non-pharmacological interventions including pulmonary rehabilitation, supplemental oxygen, appropriate treatment of comorbidities and disease-related symptoms remain crucial to optimal management. • Despite recent advances, IPF remains a fatal disease and suitable patients should be referred for lung transplantation assessment.

Original languageEnglish
Pages (from-to)82-88
Number of pages7
JournalMedical Journal of Australia
Volume208
Issue number2
DOIs
Publication statusPublished - 5 Feb 2018

Fingerprint

Idiopathic Pulmonary Fibrosis
New Zealand
Thorax
Lung
Interstitial Lung Diseases
Lung Transplantation
Cough
Respiratory Insufficiency
Dyspnea
Disease Progression
Comorbidity
Rehabilitation
Joints
Quality of Life
Oxygen
Physicians
Therapeutics

Cite this

Jo, Helen E. ; Prasad, Jyotika D. ; Troy, Lauren K. ; Mahar, Annabelle ; Bleasel, Jane ; Ellis, Samantha J. ; Chambers, Daniel C. ; Holland, Anne E. ; Lake, Fiona R. ; Keir, Gregory ; Goh, Nicole S. ; Wilsher, Margaret ; de Boer, Sally ; Moodley, Yuben ; Grainge, Christopher ; Whitford, Helen M. ; Chapman, Sally A. ; Reynolds, Paul N. ; Beatson, David ; Jones, Leonie J. ; Hopkins, Peter ; Allan, Heather M. ; Glaspole, Ian ; Corte, Tamera J. / Diagnosis and management of idiopathic pulmonary fibrosis : Thoracic society of Australia and New Zealand and lung foundation australia position statements summary. In: Medical Journal of Australia. 2018 ; Vol. 208, No. 2. pp. 82-88.
@article{f4a09dc3ee0d4674a2db44a092edb73f,
title = "Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic society of Australia and New Zealand and lung foundation australia position statements summary",
abstract = "Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with debilitating symptoms of dyspnoea and cough, resulting in respiratory failure, impaired quality of life and ultimately death. Diagnosing IPF can be challenging, as it often shares many features with other interstitial lung diseases. In this article, we summarise recent joint position statements on the diagnosis and management of IPF from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia, specifically tailored for physicians across Australia and New Zealand. Main suggestions: • A comprehensive multidisciplinary team meeting is suggested to establish a prompt and precise IPF diagnosis. • Antifibrotic therapies should be considered to slow disease progression. However, enthusiasm should be tempered by the lack of evidence in many IPF subgroups, particularly the broader disease severity spectrum. • Non-pharmacological interventions including pulmonary rehabilitation, supplemental oxygen, appropriate treatment of comorbidities and disease-related symptoms remain crucial to optimal management. • Despite recent advances, IPF remains a fatal disease and suitable patients should be referred for lung transplantation assessment.",
author = "Jo, {Helen E.} and Prasad, {Jyotika D.} and Troy, {Lauren K.} and Annabelle Mahar and Jane Bleasel and Ellis, {Samantha J.} and Chambers, {Daniel C.} and Holland, {Anne E.} and Lake, {Fiona R.} and Gregory Keir and Goh, {Nicole S.} and Margaret Wilsher and {de Boer}, Sally and Yuben Moodley and Christopher Grainge and Whitford, {Helen M.} and Chapman, {Sally A.} and Reynolds, {Paul N.} and David Beatson and Jones, {Leonie J.} and Peter Hopkins and Allan, {Heather M.} and Ian Glaspole and Corte, {Tamera J.}",
year = "2018",
month = "2",
day = "5",
doi = "10.5694/mja17.00799",
language = "English",
volume = "208",
pages = "82--88",
journal = "Medical Journal Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "2",

}

Jo, HE, Prasad, JD, Troy, LK, Mahar, A, Bleasel, J, Ellis, SJ, Chambers, DC, Holland, AE, Lake, FR, Keir, G, Goh, NS, Wilsher, M, de Boer, S, Moodley, Y, Grainge, C, Whitford, HM, Chapman, SA, Reynolds, PN, Beatson, D, Jones, LJ, Hopkins, P, Allan, HM, Glaspole, I & Corte, TJ 2018, 'Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic society of Australia and New Zealand and lung foundation australia position statements summary' Medical Journal of Australia, vol. 208, no. 2, pp. 82-88. https://doi.org/10.5694/mja17.00799

Diagnosis and management of idiopathic pulmonary fibrosis : Thoracic society of Australia and New Zealand and lung foundation australia position statements summary. / Jo, Helen E.; Prasad, Jyotika D.; Troy, Lauren K.; Mahar, Annabelle; Bleasel, Jane; Ellis, Samantha J.; Chambers, Daniel C.; Holland, Anne E.; Lake, Fiona R.; Keir, Gregory; Goh, Nicole S.; Wilsher, Margaret; de Boer, Sally; Moodley, Yuben; Grainge, Christopher; Whitford, Helen M.; Chapman, Sally A.; Reynolds, Paul N.; Beatson, David; Jones, Leonie J.; Hopkins, Peter; Allan, Heather M.; Glaspole, Ian; Corte, Tamera J.

In: Medical Journal of Australia, Vol. 208, No. 2, 05.02.2018, p. 82-88.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnosis and management of idiopathic pulmonary fibrosis

T2 - Thoracic society of Australia and New Zealand and lung foundation australia position statements summary

AU - Jo, Helen E.

AU - Prasad, Jyotika D.

AU - Troy, Lauren K.

AU - Mahar, Annabelle

AU - Bleasel, Jane

AU - Ellis, Samantha J.

AU - Chambers, Daniel C.

AU - Holland, Anne E.

AU - Lake, Fiona R.

AU - Keir, Gregory

AU - Goh, Nicole S.

AU - Wilsher, Margaret

AU - de Boer, Sally

AU - Moodley, Yuben

AU - Grainge, Christopher

AU - Whitford, Helen M.

AU - Chapman, Sally A.

AU - Reynolds, Paul N.

AU - Beatson, David

AU - Jones, Leonie J.

AU - Hopkins, Peter

AU - Allan, Heather M.

AU - Glaspole, Ian

AU - Corte, Tamera J.

PY - 2018/2/5

Y1 - 2018/2/5

N2 - Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with debilitating symptoms of dyspnoea and cough, resulting in respiratory failure, impaired quality of life and ultimately death. Diagnosing IPF can be challenging, as it often shares many features with other interstitial lung diseases. In this article, we summarise recent joint position statements on the diagnosis and management of IPF from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia, specifically tailored for physicians across Australia and New Zealand. Main suggestions: • A comprehensive multidisciplinary team meeting is suggested to establish a prompt and precise IPF diagnosis. • Antifibrotic therapies should be considered to slow disease progression. However, enthusiasm should be tempered by the lack of evidence in many IPF subgroups, particularly the broader disease severity spectrum. • Non-pharmacological interventions including pulmonary rehabilitation, supplemental oxygen, appropriate treatment of comorbidities and disease-related symptoms remain crucial to optimal management. • Despite recent advances, IPF remains a fatal disease and suitable patients should be referred for lung transplantation assessment.

AB - Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with debilitating symptoms of dyspnoea and cough, resulting in respiratory failure, impaired quality of life and ultimately death. Diagnosing IPF can be challenging, as it often shares many features with other interstitial lung diseases. In this article, we summarise recent joint position statements on the diagnosis and management of IPF from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia, specifically tailored for physicians across Australia and New Zealand. Main suggestions: • A comprehensive multidisciplinary team meeting is suggested to establish a prompt and precise IPF diagnosis. • Antifibrotic therapies should be considered to slow disease progression. However, enthusiasm should be tempered by the lack of evidence in many IPF subgroups, particularly the broader disease severity spectrum. • Non-pharmacological interventions including pulmonary rehabilitation, supplemental oxygen, appropriate treatment of comorbidities and disease-related symptoms remain crucial to optimal management. • Despite recent advances, IPF remains a fatal disease and suitable patients should be referred for lung transplantation assessment.

UR - http://www.scopus.com/inward/record.url?scp=85041507226&partnerID=8YFLogxK

U2 - 10.5694/mja17.00799

DO - 10.5694/mja17.00799

M3 - Article

VL - 208

SP - 82

EP - 88

JO - Medical Journal Australia

JF - Medical Journal Australia

SN - 0025-729X

IS - 2

ER -